Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension

Severe pulmonary arterial hypertension (PAH) is characterized by the formation of plexiform lesions and concentric intimal fibrosis in small pulmonary arteries. The origin of cells contributing to these vascular lesions is uncertain. Endogenous endothelial progenitor cells are potential contributors...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 180; no. 8; pp. 780 - 787
Main Authors Toshner, Mark, Voswinckel, Robert, Southwood, Mark, Al-Lamki, Rafia, Howard, Luke S. G, Marchesan, Denis, Yang, Jun, Suntharalingam, Jay, Soon, Elaine, Exley, Andrew, Stewart, Susan, Hecker, Markus, Zhu, Zhenping, Gehling, Ursula, Seeger, Werner, Pepke-Zaba, Joanna, Morrell, Nicholas W
Format Journal Article
LanguageEnglish
Published New York, NY Am Thoracic Soc 15.10.2009
American Thoracic Society
Subjects
Online AccessGet full text
ISSN1073-449X
1535-4970
1535-4970
DOI10.1164/rccm.200810-1662OC

Cover

More Information
Summary:Severe pulmonary arterial hypertension (PAH) is characterized by the formation of plexiform lesions and concentric intimal fibrosis in small pulmonary arteries. The origin of cells contributing to these vascular lesions is uncertain. Endogenous endothelial progenitor cells are potential contributors to this process. To determine whether progenitors are involved in the pathobiology of PAH. We performed immunohistochemistry to determine the expression of progenitor cell markers (CD133 and c-Kit) and the major homing signal pathway stromal cell-derived factor-1 and its chemokine receptor (CXCR4) in lung tissue from patients with idiopathic PAH, familial PAH, and PAH associated with congenital heart disease. Two separate flow cytometric methods were employed to determine peripheral blood circulating numbers of angiogenic progenitors. Late-outgrowth progenitor cells were expanded ex vivo from the peripheral blood of patients with mutations in the gene encoding bone morphogenetic protein receptor type II (BMPRII), and functional assays of migration, proliferation, and angiogenesis were undertaken. measurements and main results: There was a striking up-regulation of progenitor cell markers in remodeled arteries from all patients with PAH, specifically in plexiform lesions. These lesions also displayed increased stromal cell-derived factor-1 expression. Circulating angiogenic progenitor numbers in patients with PAH were increased compared with control subjects and functional studies of late-outgrowth progenitor cells from patients with PAH with BMPRII mutations revealed a hyperproliferative phenotype with impaired ability to form vascular networks. These findings provide evidence of the involvement of progenitor cells in the vascular remodeling associated with PAH. Dysfunction of circulating progenitors in PAH may contribute to this process.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
Both authors contributed equally.
Supported by a British Heart Foundation Fellowship (M.T.). This work was further funded by the Medical Research Council and received financial support from by the European Commission under the 6th Framework Programme (contract no. LSHM-CT-2005-018725, PULMOTENSION). Additional support was provided by an NIHR Biomedical Research Centre Award.
Originally Published in Press as DOI: 10.1164/rccm.200810-1662OC on July 23, 2009
Conflict of Interest Statement: M.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.V. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.A.-L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.S.G.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.Y. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. U.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. W.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.P.-Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. N.W.M. holds a research grant from Novartis.
ISSN:1073-449X
1535-4970
1535-4970
DOI:10.1164/rccm.200810-1662OC